+

WO2009073167A3 - Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions - Google Patents

Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions Download PDF

Info

Publication number
WO2009073167A3
WO2009073167A3 PCT/US2008/013271 US2008013271W WO2009073167A3 WO 2009073167 A3 WO2009073167 A3 WO 2009073167A3 US 2008013271 W US2008013271 W US 2008013271W WO 2009073167 A3 WO2009073167 A3 WO 2009073167A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary fibrosis
diagnosis
compositions
identification
related methods
Prior art date
Application number
PCT/US2008/013271
Other languages
French (fr)
Other versions
WO2009073167A2 (en
Inventor
David A. Schwartz
Lauranell Burch
Mark P. Steele
Aretha J. Herron
Kevin Brown
Marvin I. Schwarz
James E. Lloyd
Marcy Speer
Original Assignee
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services filed Critical The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Publication of WO2009073167A2 publication Critical patent/WO2009073167A2/en
Publication of WO2009073167A3 publication Critical patent/WO2009073167A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Individuals with polymorphisms in MUC5AC are more likely to develop idiopathic interstitial pneumonia (IIP) or pulmonary fibrosis. This discovery provides methods to identify susceptible individuals, and also provides approaches to treatment in this life threatening disease that previously had no known beneficial therapy. Given the relatively high prevalence of some of these SNPs in the general population, it is likely that variants MUC5AC result in susceptibility to other fibroproliferative lung diseases, including asthma, chronic obstructive lung disease, granulomatous lung diseases, and pneumonconioses.
PCT/US2008/013271 2007-12-03 2008-12-02 Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions WO2009073167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99207907P 2007-12-03 2007-12-03
US60/992,079 2007-12-03

Publications (2)

Publication Number Publication Date
WO2009073167A2 WO2009073167A2 (en) 2009-06-11
WO2009073167A3 true WO2009073167A3 (en) 2009-09-03

Family

ID=40718413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013271 WO2009073167A2 (en) 2007-12-03 2008-12-02 Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions

Country Status (1)

Country Link
WO (1) WO2009073167A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529033B1 (en) 2010-01-26 2017-05-24 National Jewish Health Methods for risk prediction, diagnosis, prognosis of pulmonary disorders
WO2014197713A2 (en) * 2013-06-05 2014-12-11 The Regents Of The University Of Colorado, A Body Corporate Molecular phenotyping of idiopathic interstitial pneumonia identifies two subtypes of idiopathic pulmonary fibrosis
EP4431150A3 (en) * 2021-12-09 2025-03-12 Splisense Ltd. Muc5b-targeted antisense oligonucleotides and related methods for modulating mucin expression
CN115322133B (en) * 2022-07-29 2023-07-04 四川大学华西医院 Application of a compound in the preparation of a viscosity-responsive fluorescent probe for pulmonary fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403638A1 (en) * 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
US20060275808A1 (en) * 2005-05-20 2006-12-07 Young Robert P Methods of analysis of polymorphisms and uses thereof
US20060292562A1 (en) * 2002-05-29 2006-12-28 Pollard Harvey B Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays
US20070099202A1 (en) * 2005-05-19 2007-05-03 Young Robert P Methods and compositions for assessment of pulmonary function and disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292562A1 (en) * 2002-05-29 2006-12-28 Pollard Harvey B Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays
EP1403638A1 (en) * 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
US20070099202A1 (en) * 2005-05-19 2007-05-03 Young Robert P Methods and compositions for assessment of pulmonary function and disorders
US20060275808A1 (en) * 2005-05-20 2006-12-07 Young Robert P Methods of analysis of polymorphisms and uses thereof

Also Published As

Publication number Publication date
WO2009073167A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
Vodicka et al. Oxidative damage in sporadic colorectal cancer: molecular mapping of base excision repair glycosylases in colorectal cancer patients
WO2005063819A3 (en) Human binding molecule against cd1a
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2011020783A3 (en) Targeted immunoconjugates
WO2009114532A3 (en) Markers for diagnosis of pulmonary inflammation and methods related thereto
JP2010516662A5 (en)
EP2639319A3 (en) Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
WO2009023509A3 (en) Therapeutic combinations useful in treating cftr related diseases
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
PL2379088T3 (en) Treatment of lung and pulmonary diseases and disorders
WO2009073167A3 (en) Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions
EP2388317A4 (en) Gene coding for human glucocaine mutant, enzyme encoded therewith, recombinant vectors and hosts, pharmaceutical compositions and their use, methods for the treatment and prevention of diseases
WO2008088861A3 (en) Gene polymorphisms predictive for dual tki therapy
WO2007132292A3 (en) Therapy for alzheimer's disease
WO2007147600A3 (en) Differential il-4 and/or il-10 cytokine expression in human cancer
WO2008088855A3 (en) Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
WO2008088876A3 (en) Tissue factor promoter polymorphisms
Loghmanee et al. Paired-Like Homeobox Gene 2B (PHOX2B) and Congenital Central Hypoventilation Syndrome (CCHS): Genotype/Phenotype Correlation in Cohort of 347 Cases.
MX2010008685A (en) Dual pharmacophores-pde4-muscarinic antagonistics.
WO2007124157A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2010019565A3 (en) Anti-ephrin b2 antibodies and their use in treatment of disease
Dunlap et al. Characterizing the Lung Microbiome in a Well-Defined Chronic Bronchitis Cohort Undergoing Bronchial Rheoplasty
WO2002036816A3 (en) Method of determining susceptibility to diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857847

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08857847

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载